Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We're making solid progress with Alaris, very constructive discussions |
| Pharmaceutical Systems delivered another quarter of double-digit growth of 10.6% driven by continued strong demand for prefillable solutions for biologics, partially offset by a slowdown in China exports of anticoagulants |
| Earlier today, we reported our results for the fourth quarter and full year of FY '23, a year characterized by strong differentiated performance driven by our BD 2025 strategy in action, impactful new innovations and our diversified business portfolio designed to help our customers navigate today's challenging environment |
| The diversification of our portfolio offers both durability through our leading positions and consistent demand for products essential to everyday patient care and strong growth through a purposeful shift into higher growth markets, anchored against three irreversible forces we see shaping health care, connected care, new care settings and chronic disease |
| Additionally, we have built capabilities and fostered a culture of operational excellence, where we make disciplined and strategic capital allocation choices, proactively address macro headwinds through our simplification programs and execute with speed and agility, all of which have and continue to play a key role in delivering strong consistent performance |
| This unique profile can be seen in both our current and 2-year performance and where our purposeful shift into higher growth markets has enabled us to drive the plus side of our targeted 5.5% plus revenue growth profile |
| We're exceeding our commitments and have outlined a strong outlook for fiscal 2024 |
| Our team drove significant margin expansion and delivered $12.21 in adjusted EPS, which represents double-digit currency-neutral growth of 11% |
| Over the past 2 years, we have made excellent progress toward our BD 2025 financial targets, delivering a 7% base organic revenue CAGR and 390 basis points of operating margin expansion |
| We increased our earnings $0.14 on an FXN basis, taking out the currency noise, which actually was favorable as that we advanced through the year |
| We also ended FY '23 with strong execution of our strategic priorities |
| Our BD 2025 strategy is demonstrating strong momentum |
| We're really pleased with the track record that we've built there |
| And so - and I think you - we're really pleased with how we've executed on the M&A that we've done |
| We are making good progress with active contracting and shipments of our first units to customers taking place ahead of schedule at the end of September |
| We are excited to deliver the benefits of the updated Alaris system to our customers and their patients, including the power of one integrated infusion platform with a centralized user interface for all major types of infusion as well as the value added through interoperability and other innovations that connect data from Alaris, Pyxis and the rest of our medication management offering into the industry's only end-to-end solution for safer, simpler and smarter medication management from the pharmacy to the floor, to the bedside |
| The clearance of the BD Alaris infusion system gives us further confidence in our ability to achieve our BD 2025 strategy and financial targets |
| So over the last 3 years, we've absorbed $1 billion of outsized inflation while improving our margin by almost 400 basis points |
| And so we have a strong, robust M&A pipeline |
| Our pharmacy automation business continues to grow double digits and it's helping our customers serve patients more efficiently and with fewer errors across various care settings |
| Our robotic microbiology platform, BD Kiestra, hit record sales this year, and we continue to drive strong double-digit growth in our BD COR and BD MAX molecular platforms, leveraging our growing installed base through menu expansion that includes our new Vaginal Panel and our Onclarity HPV assay for thin prep on BD core and now greater than 20 assays on BD MAX |
| As Chris also mentioned, we ended '23 at strong leverage, 2.6 times leverage, strong - strong cash flow, increasingly strong cash flow as we go into '24 |
| PureWick Mail has been one of the fastest ramps of a new product in our history and continues to exceed our expectations |
| Given the strong adoption, we have now designated this as a greater than $50 million incremental growth opportunity |
| Pharmaceutical Systems, which achieved 13 consecutive quarters of double-digit growth, continues to empower the delivery of new biologics, many administered by patients at home, such as the growing drug class of GLP-1s for diabetes and weight loss and other molecules, which will be delivered through our self-injection solutions |
| So really proud of the organization and strong commitment to executing against that |
| We continue to deliver double-digit FX and earnings growth, and we actually have outsized cash flow growth - the FX is unfortunate, it's unprecedented |
| We continue to drive margin improvement |
| As a matter of fact, when you think of the cash flow for BD that we're thinking of in 2024 because of that strong FXN earnings growth profile on the back of strong top line growth and the continued cash conversion that we want to improve, we're going to drive double-digit cash flow from a free cash flow standpoint |
| That creates a 50 basis point headwind through the year on margin, but that's an intentional choice and we're doing that because we have a strong cost to win program, leverage on our top line growth that we've consistently been driving and we can still drive towards our 25% goal by 2025 |
| Statement |
|---|
| It came in below - the Street in fourth quarter and just below the fiscal '23 guide |
| BD Medical performance reflects a decline in medication delivery systems resulting from softness in China driven by market dynamics, including some impacts from volume-based procurement |
| We still expect COVID-only testing to step down from the $73 million reported this year and result in a headwind to organic growth of over 25 basis points |
| Lastly, we had a discrete tax item in Q1 of last year that creates a negative comparison |
| As it relates to BD, the largest headwind we anticipate from these macro dynamics is in our China business, where we see market softness and increasing levels of volume-based procurement, predominantly impacting our MDS business along with some impact in farm systems from reduced demand as our Chinese pharmaceutical customers export business slow |
| As a result, we are projecting China to be flat to modest growth in FY '24, which creates nearly a 75 basis point headwind to our revenue growth this year |
| So on the farm systems, one is, as Chris mentioned in the prepared remarks, we're just seeing specifically within China, basically a slowdown in exports of pharmaceutical products, specifically anticoagulants from China and so lower demand as those companies are seeing significant drops in their exports |
| As it relates to Q1, we expect organic revenue growth to under index the full year by over 200 basis points, and we expect a decline in adjusted EPS versus the prior year of about $0.55 to $0.60 |
| The other thing is, as Chris mentioned, we've made some assumptions for Q1 on respiratory testing and COVID levels being notably lower than last year |
| Second, we expect operating margin to decline by around 350 basis points on a reported basis in Q1 with 200 basis points driven by inventory-related FX dynamics and another 200 basis points from the negative absorption impact from our planned inventory reductions, which we expect to partially offset through our simplification and cost mitigation initiatives while also overcoming outsized inflation |
| I think for Q1, you said 200 basis points below the annual guide |
| Based on current spot rates for illustrative purposes, currency is estimated to be a headwind with approximately 75 basis points to total company revenues and approximately 375 basis points to adjusted EPS growth on a full year basis |
| and Greater Asia despite low single-digit growth in China |
| On sales, we indicated that our organic growth in Q1 was under-indexed by 200 basis points |
| But I think the Q4 result was also impacted by the comparison to last year |
| I think in the Q1 gross margin is 350 basis points below |
| In the quarter, to your point, we talked about a 350 basis point headwind in the quarter |
| And just with the questions as I think everyone is seeing there will be some -- there is some pressure here before the open, and it kind of gives the impression of a company that is under some pressure or defensive posture, but your actions obviously are saying the opposite |
| Additionally, as it relates to sourcing from Mexico, where we have a large manufacturing footprint, the dollar weakened versus the peso by about 10%, taking the average rate over the last 4 months ending in October versus the average over the first 9 months of fiscal year '23, with the peso achieving peak rates that in that time frame had not been seen in well over 5 years |
| And first quarter is coming in pretty far substantially sequentially down |
Please consider a small donation if you think this website provides you with relevant information